Recent years have seen a huge surge of interest in oligonucleotide therapeutics, fueled by major advances in our understanding of how to make such molecules stable, selective, and efficient as drug modalities. The field is now diverse in terms of therapeutic areas being addressed, biological processes being manipulated and delivery technologies employed. In this webinar, …Read More >

WuXi AppTec offers a comprehensive platform to evaluate lead candidates targeting various types of pain, including inflammatory, neuropathic, and fibromyalgia-like pain and osteoarthritis. Our expertise and experience allow us to offer an extensive portfolio of services supporting drug discovery and development, from target discovery to translational research and clinical biomarker testing and beyond. Full-scale molecular …Read More >

WuXi AppTec xenograft and syngeneic tumor models in rats and CD47-related in vitro assay platform

Delivering comprehensive end-to-end solutions for creating, identifying, and supporting preclinical candidates, from discovery to development, with our integrated chemistry and biology research platforms.  

Structure-based design was utilized to optimize 6,6-diaryl substituted dihydropyrone and hydroxylactam to obtain inhibitors of lactate dehydrogenase (LDH) with low nanomolar biochemical and single-digit micromolar cellular potencies. Surprisingly the replacement of a phenyl with a pyridyl moiety in the chemical structure revealed a new binding mode for the inhibitors with subtle conformational change of the …Read More >